Crinetics Pharmaceuticals Ownership | Who Owns Crinetics Pharmaceuticals?


OverviewForecastRevenueFinancialsChartTranscripts

Crinetics Pharmaceuticals Ownership Summary


Crinetics Pharmaceuticals is owned by 70.04% institutional investors, 1.99% insiders, and 27.97% retail investors. Fmr is the largest institutional shareholder, holding 15.13% of CRNX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.15% of its assets in Crinetics Pharmaceuticals shares.

CRNX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockCrinetics Pharmaceuticals70.04%1.99%27.97%
SectorHealthcare Stocks 232.01%10.74%-142.75%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr14.19M15.13%$590.91M
Vanguard group9.14M9.70%$425.26M
Wellington management group llp8.38M8.94%$349.11M
Blackrock6.23M8.62%$279.06M
Blackrock funding, inc. /de7.99M8.48%$371.87M
Driehaus capital management6.48M6.91%$269.96M
Farallon capital management5.77M6.15%$240.32M
Price t rowe associates inc /md/5.31M5.66%$221.01M
Ecor1 capital4.29M4.57%$178.60M
Janus henderson group2.80M3.49%$142.90M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
New leaf venture partners141.00K13.64%$5.87M
Ecor1 capital4.29M8.57%$178.60M
Novo1.63M4.36%$67.68M
First light asset management941.52K3.70%$39.21M
Checkpoint capital260.00K3.63%$10.83M
Ghost tree capital240.00K3.37%$10.75M
Paradigm biocapital advisors lp2.55M3.02%$106.24M
Siren1.69M2.75%$70.33M
Prosight management, lp262.90K2.53%$12.24M
Driehaus capital management6.48M1.93%$269.96M

Top Buyers

HolderShares% AssetsChange
Wellington management group llp8.38M0.06%2.57M
Farallon capital management5.77M0.98%1.12M
Blackrock6.23M0.01%794.27K
Gw&k investment management1.48M0.59%625.78K
Ubs group908.19K0.01%500.47K

Top Sellers

HolderShares% AssetsChange
State street2.21M0.00%-1.02M
Jennison associates1.28M0.04%-763.13K
Vestal point capital, lp750.00K1.41%-750.00K
Lord, abbett---724.63K
T. rowe price investment management60.58K0.00%-655.59K

New Positions

HolderShares% AssetsChangeValue
Impax asset management group275.00K0.08%275.00K$12.80M
Checkpoint capital260.00K3.63%260.00K$10.83M
Sio capital management174.84K1.84%174.84K$7.28M
Rice hall james & associates174.08K0.40%174.08K$7.25M
Sector gamma as115.00K1.22%115.00K$5.35M

Sold Out

HolderChange
Jpl wealth management-5.00
Twin peaks wealth advisors-6.00
Capital performance advisors llp-8.00
Cubist systematic strategies-13.00
Northwestern mutual wealth management-16.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025204-13.92%65,989,147-38.74%700.53%119-9.85%63-11.27%
Sep 30, 20252297.01%106,238,8544.14%1130.96%1270.79%719.23%
Jun 30, 2025219-2.67%104,541,9797.66%1111.02%1293.20%64-11.11%
Mar 31, 2025227-8.84%101,882,1252.21%1090.71%125-15.54%729.09%
Dec 31, 20242432.53%99,207,04017.39%1231.11%14418.03%66-12.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv3.23M3.15%258.68K
Vanguard Health Care Inv3.19M3.11%-408.52K
Vanguard US Total Market Shares ETF2.40M2.58%2.45K
Fidelity OTC2.47M2.41%58.53K
iShares Russell 2000 ETF2.35M2.29%1.23M
Vanguard Small Cap Index2.32M2.27%172.22K
US Small-Cap Growth II Equity Comp1.49M1.46%-178.66K
T. Rowe Price New Horizons1.49M1.46%-
Vanguard Small Cap Growth Index Inv1.29M1.26%71.84K
Fidelity Select Health Care1.28M1.25%-20.11K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 03, 2026Okey Stephanie-Sell$119.01K
Mar 03, 2026Schilke Tobin Chief Financial OfficerSell$266.30K
Jan 05, 2026Kalofonos Isabel Chief Commercial OfficerSell$137.50K
Dec 01, 2025Pizzuti Dana Chief Med and Dev OfficerSell$225.10K
Nov 03, 2025Pizzuti Dana Chief Med and Dev OfficerSell$4.33K

Insider Transactions Trends


DateBuySell
2026 Q1-3
2025 Q4-4
2025 Q3-5
2025 Q2-1
2025 Q1-10

CRNX Ownership FAQ


Who Owns Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals shareholders are primarily institutional investors at 70.04%, followed by 1.99% insiders and 27.97% retail investors. The average institutional ownership in Crinetics Pharmaceuticals's industry, Biotech Stocks , is 381.47%, which Crinetics Pharmaceuticals falls below.

Who owns the most shares of Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals’s largest shareholders are Fmr (14.19M shares, 15.13%), Vanguard group (9.14M shares, 9.70%), and Wellington management group llp (8.38M shares, 8.94%). Together, they hold 33.76% of Crinetics Pharmaceuticals’s total shares outstanding.

Does Blackrock own Crinetics Pharmaceuticals?

Yes, BlackRock owns 8.62% of Crinetics Pharmaceuticals, totaling 6.23M shares as of Jun 2024. This represents 0.01% of BlackRock's total assets, with a market value of 279.06M$. In the last quarter, BlackRock increased its holdings by 794.27K shares, a 14.61% change.

Who is Crinetics Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

New leaf venture partners is Crinetics Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 13.64% of its assets in 141K Crinetics Pharmaceuticals shares, valued at 5.87M$.

Who is the top mutual fund holder of Crinetics Pharmaceuticals shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Crinetics Pharmaceuticals shares, with 3.15% of its total shares outstanding invested in 3.23M Crinetics Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools